Incyte treats first patient in its Phase 3 ruxolitinib clinical trial
Category: #health  By Mateen Dalal  Date: 2019-09-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Incyte treats first patient in its Phase 3 ruxolitinib clinical trial

Vitiligo is a common disease that causes the patient to lose skin color in random blotches. The disease can affect any body part, even affecting the inside of the patient’s mouth and hair. There are some treatments that help in restoring the color of the affected skin, however it does not treat continued loss in skin color over the affected skin. Various pharmaceutical is still developing effective therapies, so as to completely eliminate this disorder.

One such stride was made recently by Incyte Corp, an American pharmaceutical company, when it announced that it has treated its first patient in Phase 3 TRuE-V clinical study program assessing the efficacy and safety of ruxolitinib cream as monotherapy for adult and adolescent patients suffering from vitiligo.

Commenting on the development, Jim Lee, M.D., Ph.D., Head of Inflammation and Autoimmunity Group and Group Vice President, Incyte, said that vitiligo is a challenging, life-altering disease that if further complicated by the fact that there are no effective treatment options currently available in the market.

Lee further added that the launch of global Phase 3 TRuE-V clinical study program marks a major milestone for the company as it seeks to offer an effective treatment option that provides substantial improvements for patients suffering from vitiligo.

This announcement follows the company’s earlier announcement where it reported positive results from its Phase 2 ruxolitinib cream clinical trial.

Earlier in June, the company announced its 24-week results from the double-blind, randomized, vehicle-controlled, dose-ranging Phase 2 trial assessing the efficacy of ruxolitinib cream, in adult patients between the age of 18 to 75 with vitiligo.

Reportedly, the trial achieved its primary endpoint, establishing that more patients treated with the cream for 24 weeks attained a ≥50% improvement from the baseline of facial vitiligo.

Steven Stein, M.D., Chief Medical Officer, Incyte, said that the promising 24-week data shown at the World Congress of Dermatology reinforces the ability of the cream to provide an effective treatment option for people suffering from the severe autoimmune disease.

According to reports, any further details pertaining to the treatment of patient under the Phase 3 trial have not been unveiled yet.

 Source Credit: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-first-patient-treated-phase-3-clinical-trial-3

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-results-phase-2-study-ruxolitinib

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

NHS requests urgent donations of blood plasma from COVID-19 survivors
NHS requests urgent donations of blood plasma from COVID-19 survivors
By Mateen Dalal

According to reliable sources, United Kingdom National Health Service (NHS) has filed an appeal to the individuals recuperated from novel coronavirus to donate blood plasma. The organization apparently intends to treat the people who get infected dur...

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
By Mateen Dalal

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19....

Singapore’s ESR and Sabana REIT propose merger amid pandemic
Singapore’s ESR and Sabana REIT propose merger amid pandemic
By Mateen Dalal

Although the economic impact of the ongoing COVID-19 has significantly impacted prospects for Singapores REITs (Real Estate Investment Trusts), it seems that some resilient spots in the real estate sector will remain where they were. In the latest st...